Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shattuck Labs Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Shattuck Labs şirketinin kazançları yıllık ortalama -27.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında artan oldu. Gelirler yıllık ortalama 55.7% oranında azalan oldu.

Anahtar bilgiler

-27.8%

Kazanç büyüme oranı

13.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-55.7%
Özkaynak getirisi	-77.1%
Net Marj	-2,068.0%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Gelir ve Gider Dağılımı

Shattuck Labs nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:STTK Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	4	-85	20
31 Mar 24	3	-85	19
31 Dec 23	2	-87	19
30 Sep 23	1	-95	20
30 Jun 23	1	-92	20
31 Mar 23	1	-98	20
31 Dec 22	1	-102	20
30 Sep 22	30	-69	21
30 Jun 22	32	-61	19
31 Mar 22	28	-58	19
31 Dec 21	30	-45	19
30 Sep 21	1	-65	18
30 Jun 21	2	-59	16
31 Mar 21	9	-42	12
31 Dec 20	10	-37	9
30 Sep 20	11	-32	7
30 Jun 20	11	-27	6
31 Mar 20	10	-26	6
31 Dec 19	10	-24	6
31 Dec 18	22	-7	4

Kaliteli Kazançlar: STTK şu anda kârlı değil.

Büyüyen Kar Marjı: STTK şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: STTK kârlı değildir ve zararlar son 5 yılda yılda 27.8% oranında artmıştır.

Büyüme Hızlandırma: STTK 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: STTK kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: STTK hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -77.1% ) sahiptir.

Shattuck Labs Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 19%, EPS upgraded

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Price target decreased by 27% to US$8.00

Shattuck Labs, Inc. Announces Strategic Pipeline Prioritization to Include the Discontinuation of Its Clinical Program, SL-172154

Consensus revenue estimates increase by 23%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Co-Founder recently bought US$50k worth of stock

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)